Xylometazoline is a potent, direct-acting sympathomimetic amine used as a topical nasal decongestant. It is an alpha-2 adrenergic receptor agonist with some alpha-1 activity, leading to vasoconstriction of the nasal mucosal blood vessels. This reduces blood flow, decreases edema and inflammation, and provides rapid relief from nasal congestion. It is a first-line symptomatic treatment for various forms of rhinitis and sinusitis in the Indian clinical setting.
Adult: 0.1% solution: 2-3 drops or 1-2 sprays into each nostril. Usually administered every 8 to 10 hours. Do not exceed 3 applications in 24 hours.
Note: 1. Gently blow nose to clear nostrils. 2. Tilt head slightly back. 3. Insert dropper or spray tip just inside nostril, pointing away from the nasal septum. 4. Administer drops/spray while breathing in gently. 5. Avoid touching the dropper/spray tip to the nose to prevent contamination. 6. Do not use for more than 5-7 consecutive days.
Xylometazoline acts as a direct agonist on alpha-2 adrenergic receptors (with some alpha-1 activity) located on the smooth muscle of the arterioles within the nasal mucosa. This stimulation leads to vasoconstriction, reducing blood flow to the engorged nasal tissues. The resulting decrease in vascular permeability and edema leads to shrinkage of the nasal turbinates, widening of the nasal airways, and improved airflow.
Pregnancy: Category C: Animal studies have shown adverse effects. Use only if clearly needed and potential benefit justifies potential risk to the fetus. Short-term use at recommended doses is generally considered low risk, but should be avoided in the first trimester unless essential.
Driving: Unlikely to affect the ability to drive or use machines. However, if systemic side effects like dizziness or blurred vision occur, patients should avoid these activities.
| Monoamine Oxidase Inhibitors (MAOIs) e.g., Phenelzine, Tranylcypromine | Risk of severe, potentially fatal hypertensive crisis. | Contraindicated |
| Tricyclic Antidepressants (TCAs) e.g., Amitriptyline | Potentiation of pressor effects, leading to hypertension and arrhythmias. | Major |
| Other Sympathomimetic Agents (e.g., Pseudoephedrine, Phenylephrine) | Additive cardiovascular effects (tachycardia, hypertension). | Moderate |
| Beta-blockers (e.g., Propranolol) | Unopposed alpha-adrenergic stimulation may lead to severe hypertension and bradycardia. | Moderate |
| Methyldopa | Enhanced pressor response. | Moderate |
Same composition (Xylometazoline (10ml)), different brands: